Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma

Equality Impact Assessment (Guidance development) (PDF 137 KB)

Final draft guidance

Final appraisal document (PDF 287 KB)

Public committee slides (PDF 741 KB)

Draft guidance: 1

Appraisal consultation document (PDF version) (PDF 295 KB)

Appraisal consultation document (online commenting)

Committee papers (PDF 10.35 MB)

Draft scope and provisional stakeholder list comments table (post-referral) (PDF 253 KB)

Equality impact assessment (Scoping) (PDF 121 KB)

Final stakeholder list (PDF 163 KB)

Draft scope post referral (PDF 189 KB)